Characteristics of regional epidemiological indicators of chronic myeloproliferative neoplasms

Characteristics of regional epidemiological indicators of chronic myeloproliferative neoplasms

Background. Information on the epidemiological picture of chronic myeloid leukemia (CML) and, especially, Ph– chronic myeloproliferative neoplasm (MPN) in Russia is very scarce, each regional population study is important for obtaining information on the diseases in general.Aim. To analyze the regio...

Full description

Saved in:

Bibliographic Details
Main Authors:	O. Yu. Vinogradova, A. L. Neverova, M. V. Chernikov, V. P. Kosenkova, M. M. Pankrashkina, D. I. Shikhbabaeva, A. R. Vekua, V. V. Ptushkin
Format:	Article
Language:	Russian
Published:	ABV-press 2025-05-01
Series:	Онкогематология
Subjects:	myeloproliferative neoplasm chronic myeloid leukemia ph-negative chronic myeloproliferative neoplasm leukemia epidemiology population study morbidity mortality prevalence survival
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/1026
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Using the Minor Variant Finder software to identify and quantify the allelic burden level of somatic mutations in oncohematologic diseases
by: T. N. Subbotina, et al.
Published: (2020-07-01)

CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
by: Paola Guglielmelli, et al.
Published: (2010-05-01)

MYELODYSPLASTIC/MYELOPROLIFERATIVE DISEASES
by: I. N. Subortseva, et al.
Published: (2017-01-01)

Chronic myelomonocytic leukemia: A case report
by: Khevna Kansara, et al.
Published: (2024-10-01)

A Dual-Feature Framework for Enhanced Diagnosis of Myeloproliferative Neoplasm Subtypes Using Artificial Intelligence
by: Amna Bamaqa, et al.
Published: (2025-06-01)

Application of heteroduplex analysis for CALR mutation screening detection in patients with Ph-myeloproliferative neoplasms
by: T. N. Subbotina, et al.
Published: (2021-06-01)

Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker
by: Fadul A, et al.
Published: (2024-12-01)

Chronic basophilic leukemia; A rare myeloproliferative disorder and the role of flow cytometry for its diagnosis
by: Saeid Anvari, et al.
Published: (2025-03-01)

Chronic Neutrophilic Leukemia: A Case Report of Diagnosis in a 60-year-old Male
by: Marisa Setiawan, et al.
Published: (2025-01-01)

HMGB1 as a biomarker for myeloproliferative neoplasm complicated with atherosclerosis
by: Lunbi Wu, et al.
Published: (2025-05-01)

PROGRESSION OF POLYCYTHEMIA VERA TO ACUTE MYELOID LEUKEMIA FOLLOWING LONG-TERM HYDROXYUREA THERAPY: A CASE STUDY
by: Bengisu Ece Duman, et al.
Published: (2025-07-01)

Biology of Myeloproliferative Malignancies
by: AL Melikyan, et al.
Published: (2016-07-01)

A Study on the Role of Thrombophilic Genetic Disorders as a Risk Factor for Thrombotic Complications in Patients with Myeloproliferative Disorders
by: Doroteya Todorieva-Todorova, et al.
Published: (2019-08-01)

MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria
by: Mohamed A. Yassin, et al.
Published: (2020-07-01)

Association of Pruritus With Comorbidities and Survival in Myeloproliferative Neoplasms: A Systematic Review of the Literature
by: J. Saucereau, et al.
Published: (2025-06-01)

Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
by: Yoko Edahiro, et al.
Published: (2024-12-01)

Identification of Novel Risk Variants of Inflammatory Factors Related to Myeloproliferative Neoplasm: A Bidirectional Mendelian Randomization Study
by: Yang Li, et al.
Published: (2024-01-01)

Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
by: O. Yu. Vinogradova, et al.
Published: (2024-09-01)

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
by: M B Agarwal, et al.
Published: (2015-01-01)

Unraveling the impact of lysosomal dysfunction on myeloproliferative neoplasm
by: Hyundong Yoon, et al.
Published: (2024-09-01)

Megakaryocyte contribution to bone marrow fibrosis: many arrows in the quiver
by: Alessandro Malara, et al.
Published: (2018-11-01)

Immune‐dysregulation harnessing in myeloid neoplasms
by: Mohammad Jafar Sharifi, et al.
Published: (2024-09-01)

Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms
by: Xiaodong Guo, et al.
Published: (2025-08-01)

Primary and secondary myelofibrosis: ophthalmological manifestations at onset and during therapy
by: O. Yu. Vinogradova, et al.
Published: (2025-03-01)

To the problem of thrombus-hemorrhagic complications in chronic myeloproliferative neoplasias. Complicated diagnosis. Clinical case conference
by: Nikolayenko-Kamyshova T.P.
Published: (2015-09-01)

Association between JAK2V617F Mutation and Mean Platelet Volume among Myeloproliferative Neoplasm Patients
by: Mushtaq M. Khazeem, et al.
Published: (2025-04-01)

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review
by: Mostafa Najim, et al.
Published: (2024-12-01)

Clinicopathological spectrum of BCR-ABL-Negative myeloproliferative neoplasms with correlation with janus-associated kinase 2 mutation
by: Roopa Dixith, et al.
Published: (2019-01-01)

Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
by: Mohan B Agarwal, et al.
Published: (2018-01-01)

USP5 inhibition via bone marrow-targeted engineered exosomes for myeloproliferative neoplasms therapy
by: Wenjun Wang, et al.
Published: (2025-07-01)

THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION
by: Emmanouil Spanoudakis, et al.
Published: (2018-10-01)

Thrombocytosis and bleeding in myeloproliferative neoplasms: exploring clinical diversity and risk of acquired von Willebrand syndrome—insights from a UK center
by: Giulia Simini, et al.
Published: (2025-07-01)

DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications
by: Paola Barone, et al.
Published: (2025-03-01)

Molecular landscape of non-driver genes in myeloproliferative neoplasms through 333 cancer genes panel: Insights to reveal in Pakistan
by: Munazza Rashid, et al.
Published: (2025-08-01)

Not just for mature audiences: myeloproliferative neoplasms in children, adolescents, and young adults
by: Linda Resar, et al.
Published: (2025-05-01)

To the problem of thrombus-hemorrhagic complications in chronic myeloproliferative neoplasias. Complicated diagnosis. Clinical case conference.
by: T. P. Nikolayenko-Kamyshova
Published: (2015-09-01)

Dermatological Toxicity of Hydroxycarbamide
by: IN Subortseva, et al.
Published: (2018-07-01)

Case Report: Transient myeloproliferative disorder with trisomy 21 in blast cells
by: Aleksandra Zacny, et al.
Published: (2025-05-01)

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms
by: Joshua W. Bliss, et al.
Published: (2024-12-01)

Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms
by: Guangshuai Teng, et al.
Published: (2025-07-01)